85. 特発性間質性肺炎 Idiopathic interstitial pneumonia Clinical trials / Disease details
臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2021-005881-17-DK (EUCTR) | 12/09/2022 | 15/07/2022 | A study evaluating the efficacy and safety of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2) | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: TYVASO® (treprostinil) inhalation solution, for oral inhalation use Product Name: Treprostinil INN or Proposed INN: Treprostinil | UNITED THERAPEUTICS CORPORATION | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 396 | Phase 3 | Taiwan;Spain;Chile;Israel;United Kingdom;Italy;France;Mexico;Argentina;Belgium;Denmark;Australia;Peru;Germany;Netherlands;New Zealand;Korea, Republic of |